Search Results - "Self, Steve G."

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies by SEAMAN, Michael S, JANES, Holly, BHATTACHARYA, Tanmoy, LAPEDES, Alan, POLONIS, Victoria R, MCCUTCHAN, Francine E, GILBERT, Peter B, SELF, Steve G, KORBER, Bette T, MONTEFIORI, David C, MASCOLA, John R, HAWKINS, Natalie, GRANDPRE, Lauren E, DEVOY, Colleen, GIRI, Ayush, COFFEY, Rory T, HARRIS, Linda, WOOD, Blake, DANIELS, Marcus G

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial by Mullins, James I, Rolland, Morgane, Tovanabutra, Sodsai, deCamp, Allan C, Frahm, Nicole, Gilbert, Peter B, Sanders-Buell, Eric, Heath, Laura, Magaret, Craig A, Bose, Meera, Bradfield, Andrea, O'Sullivan, Annemarie, Crossler, Jacqueline, Jones, Teresa, Nau, Marty, Wong, Kim, Zhao, Hong, Raugi, Dana N, Sorensen, Stephanie, Stoddard, Julia N, Maust, Brandon S, Deng, Wenjie, Hural, John, Dubey, Sheri, Michael, Nelson L, Shiver, John, Corey, Lawrence, Li, Fusheng, Self, Steve G, Kim, Jerome, Buchbinder, Susan, Casimiro, Danilo R, Robertson, Michael N, Duerr, Ann, McElrath, M Juliana, McCutchan, Francine E

“…The STEP HIV-1 vaccine trial failed to protect volunteers from infection, but whether vaccine-driven immune responses affected the profile of viral variants in…”
Get full text

Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 gp120 Vaccine by Gilbert, Peter, Wang, Maggie, Wrin, Terri, Petropoulos, Chris, Gurwith, Marc, Sinangil, Faruk, D'Souza, Patricia, Rodriguez-Chavez, Isaac R., DeCamp, Allan, Giganti, Mike, Berman, Phillip W., Self, Steve G., Montefiori, David C.

“…Background. A candidate vaccine consisting of human immunodeficiency virus type 1 (HIV-1) subunit gp120 protein was found previously to be nonprotective in an…”
Get full text

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders by Janes, Holly, Herbeck, Joshua T, Tovanabutra, Sodsai, Thomas, Rasmi, Frahm, Nicole, Duerr, Ann, Hural, John, Corey, Lawrence, Self, Steve G, Buchbinder, Susan P, McElrath, M Juliana, O'Connell, Robert J, Paris, Robert M, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttihum, Punnee, Kaewkungwal, Jaranit, Robb, Merlin L, Michael, Nelson L, Mullins, James I, Kim, Jerome H, Gilbert, Peter B, Rolland, Morgane

“…Morgane Rolland and colleagues report that in HIV infection, a higher diversity of infecting founder viruses is associated with markers of poorer clinical…”
Get full text

Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies by Donaldson, Mitzi M., Kao, Shing-Fen, Eslamizar, Leila, Gee, Connie, Koopman, Gerrit, Lifton, Michelle, Schmitz, Joern E., Sylwester, Andrew W., Wilson, Aaron, Hawkins, Natalie, Self, Steve G., Roederer, Mario, Foulds, Kathryn E.

“…Vaccination and SIV challenge of macaque species is the best animal model for evaluating candidate HIV vaccines in pre-clinical studies. As such, robust assays…”
Get full text

Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial by Russell, Nina D, Graham, Barney S, Keefer, Michael C, McElrath, M Juliana, Self, Steve G, Weinhold, Kent J, Montefiori, David C, Ferrari, Guido, Horton, Helen, Tomaras, Georgia D, Gurunathan, Sanjay, Baglyos, Lynn, Frey, Sharon E, Mulligan, Mark J, Harro, Clayton D, Buchbinder, Susan P, Baden, Lindsey R, Blattner, William A, Koblin, Beryl A, Corey, Lawrence

“…BACKGROUND:A goal of T-cell HIV vaccines is to define the correlation between a vaccine-induced immune response and protection from HIV infection. We conducted…”
Get full text

Inclusion of Adolescents in Preventive HIV Vaccine Trials: Public Health Policy and Research Design at a Crossroads by Jaspan, Heather B, Cunningham, Coleen K, Tucker, Tim J P, Wright, Peter F, Self, Steve G, Sheets, Rebecca L, Rogers, Audrey S, Bekker, Linda-Gail, Wilson, Craig M, Duerr, Ann, Wasserheit, Judith N

“…The search for a safe effective HIV vaccine has been a centerpiece of HIV research for almost 2 decades. More than 60 clinical HIV vaccine trials have been…”
Get full text

HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features by Li, Fusheng, Horton, Helen, Gilbert, Peter B, McElrath, Juliana M, Corey, Lawrence, Self, Steve G

“…Much of the current effort in HIV-1 vaccine design is directed at achieving T-cell immunity that will result in enough immunological memory to contain HIV-1…”
Get more information

Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach by Li, Fusheng, Gilbert, Peter B, Self, Steve G

“…Antigenic variation, which is the result of amino acid substitution and genetic evolution, poses a major challenge in the development of vaccines against…”
Get more information

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials by Montefiori, David C., Karnasuta, Chitraporn, Huang, Ying, Ahmed, Hasan, Gilbert, Peter, de Souza, Mark S., McLinden, Robert, Tovanabutra, Sodsai, Laurence-Chenine, Agnes, Sanders-Buell, Eric, Moody, M. Anthony, Bonsignori, Mattia, Ochsenbauer, Christina, Kappes, John, Tang, Haili, Greene, Kelli, Gao, Hongmei, LaBranche, Celia C., Andrews, Charla, Polonis, Victoria R., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Self, Steve G., Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Tartaglia, Jim, Robb, Merlin L., Haynes, Barton F., Michael, Nelson L., Kim, Jerome H.

“…Background. A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with…”
Get full text

Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine (AIDSVAX™ B/B) by Gilbert, Peter, Wang, Maggie, Wrin, Terri, Petropoulos, Chris, Gurwith, Marc, Sinangil, Faruk, D'Souza, Patricia, Rodriguez-Chavez, Isaac R., DeCamp, Allan, Giganti, Mark, Berman, Phillip W., Self, Steve G., Montefiori, David C.

Get full text